Prognostic values of DLK1 for surgery and imatinib mesylate adjuvant therapy in gastrointestinal stromal tumors.

about

Prognostic values of DLK1 for surgery and imatinib mesylate adjuvant therapy in gastrointestinal stromal tumors.

Item

http://www.wikidata.org/entity/Q37447959

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Prognostic values of DLK1 for ...... strointestinal stromal tumors.

@en

Prognostic values of DLK1 for ...... strointestinal stromal tumors.

@nl

type

Item

label

Prognostic values of DLK1 for ...... strointestinal stromal tumors.

@en

Prognostic values of DLK1 for ...... strointestinal stromal tumors.

@nl

prefLabel

Prognostic values of DLK1 for ...... strointestinal stromal tumors.

@en

Prognostic values of DLK1 for ...... strointestinal stromal tumors.

@nl

P1476

Prognostic values of DLK1 for ...... strointestinal stromal tumors.

@en

P2093

Chaojie Wang

http://www.w3.org/2001/XMLSchema#string

Hui Cao

http://www.w3.org/2001/XMLSchema#string

Jia Xu

http://www.w3.org/2001/XMLSchema#string

Lin Tu

http://www.w3.org/2001/XMLSchema#string

Ming Wang

http://www.w3.org/2001/XMLSchema#string

Wenyi Zhao

http://www.w3.org/2001/XMLSchema#string

Yeqian Zhang

http://www.w3.org/2001/XMLSchema#string

Zizhen Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line

Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation

The EGF-like protein dlk1 inhibits notch signaling and potentiates adipogenesis of mesenchymal cells

Prognostic value of Ki67 index in gastrointestinal stromal tumors.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

REporting recommendations for tumour MARKer prognostic studies (REMARK)

Genomic imprinting at the mammalian Dlk1-Dio3 domain.

Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

P304

2700-2712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27904782

http://www.w3.org/2001/XMLSchema#string

P932

5126284

http://www.w3.org/2001/XMLSchema#string